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Introduction 
Beta-adrenergic agents have been used in pregnant women for the treatment of premature labor and for 
the treatment of asthma.  Concerns have been expressed that exposure to terbutaline, a beta-2 adrenergic 
agonist, may increase the risk of autism spectrum disorders (ASDs) in the offspring.  This hypothesis 
deserves critical review, given the number of patients exposed to the drug in the last two decades. The 
results are important to both the obstetricians and patients who weigh the risks and benefits of 
interventions and to the pediatricians who counsel the families of affected children.   
We have conducted an examination of the human and animal studies that have been used to support 
this hypothesis in a recent review1, and we reach a different conclusion.  We find no support for the 
hypothesis that the use of terbutaline as a tocolytic agent is associated with the subsequent development of 
ASDs. 
The ASDs are common neurodevelopmental disorders, occurring in about 1/150 to 1/100 children2.  
They are diagnosed by deficits in social interaction and communication and by restricted and repetitive 
behaviors and interests; the symptoms appear during the first three years of life 3.   
Family and twin studies demonstrate that these disorders are  heritable, with estimates of heritability 
approaching 90%4.  However, the genetic etiology is complex, with many loci involved and none that 
account for more than a small fraction of cases5.  Many developmental pathways seem to be involved, 
including those that have roles in initiating or maintaining synapses 6,7.  The penetrance of the genetic 
liability factors is variable, so that symptoms differ, even in pairs of monozygotic twins8.  The largest 
 3 
genome scan to date has added to this confusing picture the etiological role of structural chromosomal 
anomalies (copy number variants), some of which arise de novo 9.  This unexpected result has been 
verified by other groups10. 
The known environmental risk factors for ASDs account for a small number of cases but are interesting 
because they share critical periods of exposure in the first trimester11.  The identification of environmental 
risk factors is especially important because, unlike genetic risk factors, they should be preventable.  Thus, 
it is reasonable to ask whether there is evidence that medications, such as terbutaline, to which pregnant 
women may be exposed increase the risk for an ASD outcome in the offspring.  Our argument is not with 
the intent, but with the quality of the evidence presented in the review by Witter et al. 1, which we now 
describe. 
 
Human Studies 
 Is fetal exposure to terbutaline associated with neurobehavioral defects?  The review cites Stein et 
al.12 as the source that shows terbutaline exposure has been associated with expressive language delay; 
however, that article does not report a study, but the presentation of a “Challenging Case” with responses 
by four pediatricians from different backgrounds. None of the commentators suggested that the patient’s 
language delay might be associated with her prenatal exposure to terbutaline. This source does not offer 
any evidence to support the hypothesis of a link between ASD and exposure to terbutaline.  
 The second reference cited in the article is to a study reported by several of the same authors of the 
review. 13The review states that the earlier paper demonstrates increased concordance for ASDs in 
dizygotic twins after terbutaline treatment in utero. However, a careful review of the data found no 
significant association of concordance with terbutaline exposure in the whole twin sample (36 cases). Only 
when the investigators divided the sample into smaller subgroups and focused on twin pairs who were 
both male and had no other cases of ASDs in their family were they able to find a significant association 
between drug exposure and outcome. This group of 16 twin pairs should have been at increased risk for 
ASDs because they were male, but at decreased risk because of the absence of ASDs in their families.  It is 
unclear why such a subgroup would ever be selected for study a priori.  If it was selected a posteriori, 
then the results should be considered “hypothesis-generating” at best. 
Another aspect of this publication deserves comment. For all comparisons of “exposed” to “non-
exposed” twins, two twin pairs with short exposures were counted as “unexposed”. No explanation was 
given to justify re-categorizing these twins. Because both of these pairs were discordant, moving them to 
 4 
the unexposed category had a major effect on the results. For example, the p value for the whole sample 
difference in concordance between exposed and unexposed pairs was reported as p = 0.157 in the paper. 
Had the briefly-exposed pairs been included as “exposed,” the p value would have been 0.471. In the 
selected group of cases composed of male pairs with no other siblings diagnosed with ASDs, in which the 
authors reported a significant increase in concordance after terbutaline (P =.035) that p value would have 
been 0.118. Thus, the only significant effect reported for concordance is dependent on the re-classification 
of briefly-exposed twin pairs. The authors might argue that the relative risks for their comparisons are 
greater than one, but they are not significantly greater than one. That is the reason confidence intervals are 
calculated.  
 As evidence that terbutaline exposure for tocolysis or asthma is associated with autism, the 
publication cites an oral presentation at a meeting. 14The full report of that study is now available. 15  The 
design of the study is peculiar, in that the eight terbutaline-exposed recruited children (from just two 
families) had already been diagnosed with autism. Their performance on a battery of neuropsychological 
tests was reported to differ from the performance of typically-developing children. It is not clear how this 
result can be interpreted to support a teratogenic effect of terbutaline, as subjects with an ASD diagnosis 
would surely be expected to differ in many ways from subjects without a diagnosis. The design makes the 
study uninterpretable.  
 Another line of evidence offered to support the hypothesis that beta-2-adrenergic agonists are 
harmful to the conceptus is a study examining the risk of an ASD diagnosis in the offspring of mothers 
who have autoimmune disorders 16. The review describes this as a study of asthma and suggests that the 
risk must be related to the use of beta-2-adrenergic agonists by asthma patients. However, the only 
autoimmune condition that was a significant risk factor in the cited study was psoriasis, a condition not 
treated with these agonists.  
 The fifth reference is a personal communication about an unpublished study. An abstract of that 
study is available. 17 The authors of the article under review contend that the data show that beta-2- 
adrenergic agonist exposure during early pregnancy produces an increased risk for ASDs. In contrast, the 
abstract reports no such finding: instead, there was no effect of exposure in the first, second or third 
trimester. The only significant effect was from the use of beta-2-adrenergic agonists preconception. These 
results do not support the hypothesis that terbutaline exposure in the third trimester increases the risk of 
ASD. 
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Although the issues we have identified herein address a fraction of the review article, they suggest a 
very loose interpretation of the findings in the literature. Although we respect the right of authors to select 
studies that support their views, the scientific community would expect an accurate description and a 
balanced report of the studies cited.  
 
Animal Studies 
The review1 describes many animal studies to support the hypothesis that terbutaline is teratogenic 
in late pregnancy, leading to lasting changes in neurotransmitter function, behavior, and brain morphology. 
However, it is important to note that the studies cited come almost exclusively from one research group, 
using the same dose at the same stage of development for the same number of repeated doses. If there is 
any error in the dose or timing or duration of exposure chosen to mimic terbutaline as a tocolytic therapy, 
it is shared by all the papers cited.   
The dose selected is based on pharmacologic evidence that adult rats clear terbutaline more rapidly 
than adult humans. 18,19 Therefore, the dose to which rats were exposed was purposely higher than the 
doses typically delivered to women in preterm labor. However, it is well known that developing humans 
and rats do not clear xenobiotics at the same rate as adults.20  The problem is that no data are available that 
compare clearance rates in the human fetus and the neonatal rat (a stage of rat development often used to 
model the 3rd trimester of human pregnancy). Without that information, there is no way to judge whether 
the doses in the rat studies are equivalent to those used in humans. Similarly, the only data available are 
from animals given repeated doses over four days. What would be the corresponding length of exposure in 
humans?  We do not know. 
 None of the studies provide information on the dose-response curve of terbutaline exposure 
in neonatal rats for the endpoints measured. This information is needed to interpret the risk of 
teratogenicity after terbutaline exposure. Very few teratogens have been studied extensively for their dose-
response characteristics, but when many laboratories perform studies of the same teratogen, there are often 
enough differences in method between studies to offer some insights into the importance of dose, timing, 
and duration of exposure. This information does not exist with terbutaline.   
 In the review, the neuropathology of terbutaline-exposed rats 21 is described as similar to the 
neuropathology reported for human cases with an ASD diagnosis. The accuracy of this claim is not easy to 
assess, because, of the brain regions studied in the animal model (hippocampus, somatosensory cortex and 
cerebellum), only the cerebellum has been observed to be consistently abnormal in human cases.22,23 The 
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animal finding of reduced Purkinje cell numbers does agree with the human findings. The result of 
reduced size of cortical neurons in the exposed animals is not similar to anything reported in humans. 
Finally, there is the result of gliosis observed in the CA3 region of the hippocampus in the treated rats. 
Most pathology studies in cases of ASD have not reported the presence of gliosis. However, Bailey et 
al.23did report astrogliosis restricted to the cerebellum in three of their six cases. Vargas et al.24 observed 
and quantified widespread astrogliosis and microgliosis in each of their human cases. The glial reactivity 
was greatest in the cerebellum. The animal finding of gliosis limited to one region of the hippocampus 
does not appear similar to any of the human findings. However, subsequent to the publication of the 
Vargas paper in 2005, the same group of investigators who reported the very restricted gliosis in 2004 
used the immunocytochemical methods of Vargas and reported widespread astrogliosis and microgliosis in 
both grey matter and white matter of cortex and cerebellum in terbutaline-exposed rats.25  The meaning of 
these results is not clear, because gliosis is not a finding restricted to autism. 
 The authors of the review describe the behavioral effects reported in rats exposed in the 
neonatal period to terbutaline 25 as “similar to those found in autism.” The significant effects observed 
included increased activity in an open field and increased reactivity to noise. These effects are so 
nonspecific that they can hardly be described as confirming parallelism with autism. The same study25 
included one measure that is a much better test of parallelism. Pre-Pulse Inhibition was measured in 
terbutaline-exposed rats and controls. This neurophysiological measure is clearly depressed in human 
cases of ASD26,27 and in a popular animal model of autism based on exposure of rat embryos to valproic 
acid at the time of neural tube closure.28 In contrast, terbutaline exposure had no effect on Pre-Pulse 
Inhibition. Thus, the idea that terbutaline-exposed animals exhibit behaviors similar to those observed in 
autism is not convincing.  
Comment 
An important issue not addressed by Witter et al.1 is the fact that premature birth itself is associated 
with an increase in the risk of neurobehavioral problems, including ASDs. For example, a recent paper by 
MacKay and others29 examined the length of gestation and the later need for special educational services. 
Delivery before 40 weeks was associated with a significantly increased risk of educational problems over 
the whole range of gestation.  A recent paper by Buckmayer and others30 analyzed the effect of 
prematurity on ASDs in an unusually large number of cases.  The result was that the significant odds ratio 
for the whole sample disappeared if analyses controlled for indications of morbidity during gestation (e.g., 
cases with congenital malformations) or at the time of birth (e.g., cases with low APGAR scores).  Thus, it 
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remains unclear whether prematurity is an etiological factor in the development of ASDs, or whether it is 
simply an indication that the conceptus has sustained harm in some way.  
Indeed, one of the studies that Witter and others1 describe is an excellent demonstration of the idea 
that even threatened premature delivery may be evidence of injury.  Pitzer et al.31 compared four groups 
for neurological and psychiatric morbidity in childhood.  Two groups were born prematurely, one without 
treatment and one with unsuccessful tocolysis.  Compared to children born at term without incident both 
groups born early had elevated rates of neurobehavioral problems, and they did not differ from each other.  
The fourth group included children who were born at term after successful tocolytic treatment.  The rate of 
neurobehavioral problems in this group was much higher than that seen in children born at term without 
treatment, but it was similar to the two groups born prematurely. Witter et al.1 interpret the study as 
supporting the idea that longer duration of therapy is critical to an adverse outcome, assuming that the 
children who came to term were exposed for longer than those born prematurely.  However, Pitzer’s 
group31 examined a subset of cases for whom duration of exposure and cumulative dose were known. The 
authors reported that the group born prematurely was treated for a median of 18 days with a median 
cumulative dose of 66 mg, while the group born at term was treated for a median of 10 days with a median 
cumulative dose of 29 mg.  The simplest conclusion to be drawn from this study is that tocolysis has no 
effect on neurobehavioral outcomes, but threatened premature labor may have a substantial effect, even if 
it is treated successfully. 
Several publications have addressed the utilization of beta-2 adrenergic agonists, including 
terbutaline, for the treatment of preterm labor. Terbutaline readily crosses the human placenta 32.  In 
review articles by Lam et al. 33 and Goldenberg 34, the benefits of beta-2-adrenergic agonists in general, 
and terbutaline in particular, are discussed. Surely, larger human studies with long–tern follow up might 
raise new concerns, but the present literature does not support the hypothesis that beta-2 adrenergic 
agonists used for tocolysis are associated with ASDs in the offspring.  There is no reason to make 
recommendations for clinical care based on an unsubstantiated hypothesis. 
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